Search
Ulimorelin
go.drugbank.com/drugs/DB12128InvestigationalUlimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a
Categories: MATE 1 Inhibitors, P-glycoprotein inducersProducts: LORBRENA® 25 MG, LORBRENA® 100 MGGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. … Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesProducts: XOSPATA® FILM-COATED TABLETS 40MGGepirone
go.drugbank.com/drugs/DB12184ApprovedIt was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant. … It represents a novel class of antidepressants that selectively targets the 5HT<sub>1A</sub> receptors, thus possessing a more favorable side effects profile with comparable incidence of sexual dysfunction
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingExatecan
go.drugbank.com/drugs/DB12185InvestigationalExatecan has been used in trials studying the treatment of Sarcoma, Leukemia, Lymphoma, Lung Cancer, and Liver Cancer, among others.
Categories: Topoisomerase I InhibitorsObatoclax
go.drugbank.com/drugs/DB12191InvestigationalObatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingCapivasertib
go.drugbank.com/drugs/DB12218ApprovedInvestigationalTherefore, targeting the PIK3/AKT pathway presents a promising approach for the treatment of breast cancer, leading to the development of capivasertib, a pan-AKT kinase inhibitor. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsBunazosin
go.drugbank.com/drugs/DB12230InvestigationalBunazosin has been used in trials studying the treatment of High Blood Pressure.
Categories: Peripheral alpha-1 blockers, Heterocyclic Compounds, 2-RingAlpha-galactosylceramide
go.drugbank.com/drugs/DB12232InvestigationalKRN7000 has been used in trials studying the treatment of Lung Cancer, Chronic Hepatitis C, Hepatitis B, Chronic, Unspecified Adult Solid Tumor, Protocol Specific, and Prevention of GvHD in Patients With
Synonyms: 1-O-(α-D-galactopyranosyl)-N-hexacosanoylphytosphingosine